GlassScriptPhysician profile
John L Wheat
NPI 1265876213
$3,186.85
in general payments reported to CMS, 2019-2025
25 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 87% of Preventive Medicine/Occupational Environmental Medicine providers received nationally (typical 2025 total: $76.00).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.64 · 2021: $38.65 · 2022: $184 · 2023: $767 · 2024: $1,131 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.66 | 2021-2025 | Vraylar |
| Amgen INC. | $433.82 | 2022-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $402.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $387.76 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.97 | 2023-2025 | Caplyta |
| Dexcom, INC. | $150.18 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $127.39 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $122.40 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $93.62 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $89.73 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.20 | 2023-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $56.57 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $53.62 | 2022-2025 | Auvelity |
| Indivior INC. | $51.39 | 2025 | Sublocade |
| Lundbeck LLC | $45.95 | 2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $38.25 | 2023-2024 | Vivitrol, Vivitrol |
| Medtronic, INC. | $37.81 | 2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $27.17 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $26.76 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Biomerieux INC | $23.40 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Braeburn INC. | $19.85 | 2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $17.05 | 2025 | Qelbree, Xyosted, Tlando |
| Halozyme INC | $16.64 | 2023 | |
| Abbott Laboratories | $16.16 | 2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $15.83 | 2023 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wheat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.